Expression profile of immunoregulatory factors in canine tumors
Copyright © 2022 Elsevier B.V. All rights reserved..
Cancers utilize a variety of molecules to escape host immune responses. Better understanding the immune environment surrounding cancer may facilitate application of innovative cancer immunotherapies, such as immune checkpoint inhibitors, to dogs as well as humans. In this study, we screened the expression of 20 immune regulatory molecules in diverse canine tumors (n = 59). Quantitative RT-PCR (qPCR) analysis revealed that some immune regulatory molecules, such as LGALS9 (coding Galectin-9) and CD48, were expressed in most canine tumors, but other molecules, such as CD274 (coding PD-L1), IL4I1, PVR, TNFSF18, ICOSLG, and TNFSF4, were rarely expressed. NECTIN2 was highly expressed in epithelial tumors but was low in non-epithelial tumors. In contrast, VSIR and CD200 expressions were low in epithelial tumors but high in non-epithelial tumors. Interestingly, several tumors expressed distinctive immunoregulatory factors. Hepatocellular carcinomas expressed FGL1, mast cell tumors expressed PDCD1LG2 (coding PD-L2), transitional cell carcinomas expressed VTCN1 (coding B7x), and lymphomas and squamous cell carcinomas expressed CD70. Consistent with qPCR results, immunofluorescence staining confirmed that hepatocellular carcinomas expressed FGL-1 protein. Thus, this study reveals the expression profile of immunoregulatory molecules in canine tumors and opens the door to better understanding the relationship between canine tumors and host immunity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:253 |
|---|---|
| Enthalten in: |
Veterinary immunology and immunopathology - 253(2022) vom: 20. Nov., Seite 110505 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murakami, Kohei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9001-32-5 |
|---|
| Anmerkungen: |
Date Completed 22.11.2022 Date Revised 22.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vetimm.2022.110505 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348418701 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348418701 | ||
| 003 | DE-627 | ||
| 005 | 20231226040141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vetimm.2022.110505 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348418701 | ||
| 035 | |a (NLM)36327941 | ||
| 035 | |a (PII)S0165-2427(22)00125-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murakami, Kohei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expression profile of immunoregulatory factors in canine tumors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2022 | ||
| 500 | |a Date Revised 22.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Cancers utilize a variety of molecules to escape host immune responses. Better understanding the immune environment surrounding cancer may facilitate application of innovative cancer immunotherapies, such as immune checkpoint inhibitors, to dogs as well as humans. In this study, we screened the expression of 20 immune regulatory molecules in diverse canine tumors (n = 59). Quantitative RT-PCR (qPCR) analysis revealed that some immune regulatory molecules, such as LGALS9 (coding Galectin-9) and CD48, were expressed in most canine tumors, but other molecules, such as CD274 (coding PD-L1), IL4I1, PVR, TNFSF18, ICOSLG, and TNFSF4, were rarely expressed. NECTIN2 was highly expressed in epithelial tumors but was low in non-epithelial tumors. In contrast, VSIR and CD200 expressions were low in epithelial tumors but high in non-epithelial tumors. Interestingly, several tumors expressed distinctive immunoregulatory factors. Hepatocellular carcinomas expressed FGL1, mast cell tumors expressed PDCD1LG2 (coding PD-L2), transitional cell carcinomas expressed VTCN1 (coding B7x), and lymphomas and squamous cell carcinomas expressed CD70. Consistent with qPCR results, immunofluorescence staining confirmed that hepatocellular carcinomas expressed FGL-1 protein. Thus, this study reveals the expression profile of immunoregulatory molecules in canine tumors and opens the door to better understanding the relationship between canine tumors and host immunity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B7x | |
| 650 | 4 | |a CD70 | |
| 650 | 4 | |a FGL-1 | |
| 650 | 4 | |a Immune checkpoint | |
| 650 | 4 | |a PD-L2 | |
| 650 | 4 | |a Tumor immunity | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Fibrinogen |2 NLM | |
| 650 | 7 | |a 9001-32-5 |2 NLM | |
| 650 | 7 | |a L-Amino Acid Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.4.3.2 |2 NLM | |
| 650 | 7 | |a OX40 Ligand |2 NLM | |
| 700 | 1 | |a Miyatake, Saki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamae, Jiro |e verfasserin |4 aut | |
| 700 | 1 | |a Saeki, Kanna |e verfasserin |4 aut | |
| 700 | 1 | |a Shinya, Mizutani |e verfasserin |4 aut | |
| 700 | 1 | |a Akashi, Natsuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mitsui, Ikki |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Kosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Saeki, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Maeta, Noritaka |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Teppei |e verfasserin |4 aut | |
| 700 | 1 | |a Okamura, Yasuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmi, Hiroaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Veterinary immunology and immunopathology |d 1979 |g 253(2022) vom: 20. Nov., Seite 110505 |w (DE-627)NLM012599875 |x 1873-2534 |7 nnns |
| 773 | 1 | 8 | |g volume:253 |g year:2022 |g day:20 |g month:11 |g pages:110505 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vetimm.2022.110505 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 253 |j 2022 |b 20 |c 11 |h 110505 | ||